Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7334801

COc1ccc2ccc(C=NN)cc2c1NC(=O)O.O=C(O)C(F)(F)F

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.36
TDP1 Q9NUW8 1/20 0.36
HTT P42858 3/20 0.36
POLB P06746 3/20 0.36
CYP1A2 P05177 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP2C9 P11712 2/20 0.36
MAPT P10636 4/20 0.35
GAA P10253 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
PLAU P00749 1/20 0.35
TRPM5 Q9NZQ8 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
UBE2N P61088 1/20 0.35
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
CYP3A4 P08684 2/20 0.35
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7337424 0.79 PLAU (0.46) KDM4EPOLBMAPTPLAUMEN1
Trifluoroacetic Acid SCHEMBL7336995 0.79 PLAU (0.46) KDM4EPOLBMAPTPLAUMEN1
Trifluoroacetic Acid SCHEMBL7336904 0.79 PLAU (0.59) CYP1A2CYP2C19CYP2C9PLAU
Trifluoroacetic Acid SCHEMBL7345802 0.78 PLAU (0.55) KDM4EPOLBMAPTGAARAB9A
Trifluoroacetic Acid SCHEMBL7345787 0.78 PLAU (0.55) KDM4EPOLBMAPTGAARAB9A
Trifluoroacetic Acid SCHEMBL7456126 0.77 TRPV1 (0.40) KDM4EMAPTGAARAB9APLAU
Trifluoroacetic Acid SCHEMBL7334991 0.77 PLAU (0.41) KDM4EPOLBMAPTNPC1RAB9A
Trifluoroacetic Acid SCHEMBL7344754 0.77 KDM4E (0.41) KDM4EHTTPOLBMAPTGAA
Trifluoroacetic Acid SCHEMBL7344763 0.77 KDM4E (0.41) KDM4EHTTPOLBMAPTGAA
Trifluoroacetic Acid SCHEMBL7334981 0.77 PLAU (0.41) KDM4EPOLBMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 KDM4E 4285/4885TDP1 1364/4885HTT 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.